Underutilization of BRCA1/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at risk

Genetics in Medicine

Volumn 13, Issue 4, 2011, Pages 349-355

  Levy, Douglas E ^a,b   Byfield, Stacey D ^c   Comstock, Catherine B ^d   Garber, Judy E ^b,e   Syngal, Sapna ^b,e,f   Crown, William H ^c   Shields, Alexandra E ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c i3 Global   (Canada)

^d Independent Consultant   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

BRCA1 2; breast cancer; ethnicity; race

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; ARTICLE; ASIAN; BREAST CANCER; CANCER THERAPY; CAUCASIAN; ETHNICITY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; HEALTH INSURANCE; HEALTH MAINTENANCE ORGANIZATION; HIGH RISK PATIENT; HISPANIC; HUMAN; INCOME; JEW; MAJOR CLINICAL STUDY; NEGRO; RACE DIFFERENCE;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENETIC TESTING; HISPANIC AMERICANS; HUMANS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; WOMEN;

EID: 79955009383     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3182091ba4     Document Type: Article

References (45)

1. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003;21:2397-2406.
2. U.S. Preventive Services Taskforce. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005;143:355-361.
3. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian V. 1.2009, 2009. Available at: http://www.nccn.org/professionals/physician-gls/PDF/genetics-screening.pdf. Accessed September 28, 2009.
4. American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, adopted on February 20, 1996. J Clin Oncol 1996;14:1730-1736; discussion 1737-1740.
5. Myriad Genetics. Myriad Genetics awarded three U.S. patents and eight international patents, 2001; news release. Available at: http://www.myriad.com/ news/release/210288. Accessed May 14,2008.
6. National Comprehensive Cancer Network. Colorectal cancer screening V. 1.2009. 2009. Available at: http://www.nccn.org/professionals/physician-gls/PDF/ colorectal-screening.pdf. Accessed September 28, 2009.
7. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005;23:7491-7496. (Pubitemid 46291812)
8. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:2328-2335. (Pubitemid 41115389)
9. Levy DE, Garber JE, Shields AE. Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization. J Gen Intern Med 2009;24:822-828.
10. Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA 2005;293:1729-1736.
11. Susswein LR, Skrzynia C, Lange LA, Booker JK, Graham ML 3rd, Evans JP. Increased uptake of BRCA1/2 genetic testing among African American women with a recent diagnosis of breast cancer. J Clin Oncol 2008:26:32-36.
12. Breslin TM, Morris AM, Gu N, et al. Hospital factors and racial disparities in mortality after surgery for breast and colon cancer. J Clin Oncol 2009; 27:3945-3950.
13. Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 2004;54:78-93. (Pubitemid 38519418)
14. Schwartz MD, Lerman C, Brogan B, et al. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomarkers Prev 2005;14:1003-1007. (Pubitemid 40478572)
15. Ethnic Technologies LLC. South Hackensack, NJ: The E-Tech Process, 2008. Available at: http://www.ethnictechnologies.com/multicultural-information/etech- process/index.html?cart=12541643606273702. Accessed April 15, 2010.
16. DeFrank JT, Bowling JM, Rimer BK, Gierisch JM, Skinner CS. Triangulating differential nonresponse by race in a telephone survey. Prev Chronic Dis 2007;4:A60.
17. Tobin G, Groeneman S. Surveying the Jewish population in the United States. San Francisco, CA: Institute for Jewish and Community Research, 2003. Available at: http://www.jewishdatabank.org/Archive/N-HARI-2001-Surveying-the- Jewish-Population-of-the-United-States.pdf. Accessed October 6, 2010.
18. KnowledgeBase Marketing. AmeriLINK data, 2008. Richardson, TX: KnowledgeBase Marketing. Available at: http://www2.kbm1.com/Documents/AmeriLINK- brochure.pdf. Accessed September 28, 2009.
19. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian V. 1.2004, 2004.
20. Meyer LA, Anderson ME, Lacour RA, et al. Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: missed opportunities. Obstet Gynecol 2010;115:945-952.
21. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458-1465. (Pubitemid 29493800)
22. Rosenthal E. Shortage of genetics counselors may be anecdotal, but need is real. Oncol Times 2007;29:34-36.
23. Armstrong K, Weber B, Ubel PA, Guerra C, Schwartz JS. Interest in BRCA1/2 testing in a primary care population. Prev Med 2002;34:590-595. (Pubitemid 34971660)
24. Hughes C, Gomez-Caminero A, Benkendorf J, et al. Ethnic differences in knowledge and attitudes about BRCA1 testing in women at increased risk. Patient Educ Couns 1997;32:51-62. (Pubitemid 27395979)
25. Wideroff L, Vadaparampil ST, Breen N, Croyle RT, Freedman AN. Awareness of genetic testing for increased cancer risk in the year 2000 National Health Interview Survey. Community Genet 2003;6:147-156. (Pubitemid 38916113)
26. Vadaparampil ST, Wideroff L, Breen N, Trapido E. The impact of acculturation on awareness of genetic testing for increased cancer risk among Hispanics in the year 2000 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2006;15:618-623.
27. Sankar P, Wolpe PR, Jones NL, Cho M. How do women decide? Accepting or declining BRCA1/2 testing in a nationwide clinical sample in the United States. Community Genet 2006;9:78-86.
28. Armstrong K, Calzone K, Stopfer J, Fitzgerald G, Coyne J, Weber B. Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 2000;9:1251-1254.
29. Hall M, Olopade OI. Confronting genetic testing disparities: knowledge is power. JAMA 2005;293:1783-1785.
30. Peterson EA, Milliron KJ, Lewis KE, Goold SD, Merajver SD. Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarkers Prev 2002;11:79-87. (Pubitemid 34118316)
31. Peters N, Rose A, Armstrong K. The association between race and attitudes about predictive genetic testing. Cancer Epidemiol Biomarkers Prev 2004; 13:361-365. (Pubitemid 38737459)
32. Jones JH. Bad blood: the Tuskegee syphilis experiment. New York: Free Press, 1993.
33. Gamble VN. Tuskegee lessons, 2002. Available at: http://www.npr.org/ programs/morning/features/2002/jul/tuskegee/commentary.html. Accessed July 30, 2010.
34. King PA. The past as prologue: race, class, and gene discrimination. In: Annas GJ, Elias S, editors. Gene mapping: using law and ethics as guides. New York: Oxford University Press. 1992, pp. 94-111.
35. Harmon A. Congress passes bill to bar bias based on genes. The New York Times. May 2, 2008.
36. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20:1480-1490. (Pubitemid 34260526)
37. Hall MJ, Reid JE, Burbidge LA, et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 2009;115:2222-2233.
38. Weitzel JN, Lagos V, Blazer KR, et al. Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 2005;14:1666-1671. (Pubitemid 40995077)
39. Bach PB, Pham HH, Schrag D, Tate RC, Hargraves JL. Primary care physicians who treat blacks and whites. N Engl J Med 2004;351:575-584. (Pubitemid 39028925)
40. Jha AK, Orav EJ, Li Z, Epstein AM. Concentration and quality of hospitals that care for elderly black patients. Arch Intern Med 2007;167:1177-1182. (Pubitemid 46919821)
41. Hasnain-Wynia R, Baker DW, Nerenz D, et al. Disparities in health care are driven by where minority patients seek care: examination of the hospital quality alliance measures. Arch Intern Med 2007;167:1233-1239. (Pubitemid 46998493)
42. Shields AE, Burke W, Levy DE. Differential use of available genetic tests among primary care physicians in the United States: results of a national survey. Genet Med 2008;10:404-414.
43. Thompson HS, Valdimarsdottir HB, Duteau-Buck C, et al. Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women. Cancer Epidemiol Biomarkers Prev 2002;11:1579-1585. (Pubitemid 36020010)
44. Garnick DW, Hendricks AM, Comstock CB. Measuring quality of care: fundamental information from administrative datasets. Int J Qual Health Care 1994;6:163-177.
45. Collins FS, Guttmacher AE. Genetics moves into the medical mainstream. JAMA 2001;286:2322-2324. (Pubitemid 33063155)